Brittany L. Howard, PA-C
Program Director
Bariatric and Metabolic Surgical Services
Womack Army Medical Center
Fort Liberty, N.C.

1. Identify, evaluate, and assess appropriate patients for treatment with antiobesity medications (AOM).
2. Compare and differentiate AOMs used to treat obesity.
3. Educate patients regarding obesity treatment selection.
4. Explain the prior authorization process for AOM.
5. Describe limitations concerning active-duty service members (ADSM) use of AOMs.

Army Maj. Benjamin Custer, MD, MPH&TM 
Chair, Infection Prevention and Control
Walter Reed National Military Medical Center
Assistant Professor of Medicine
Uniformed Services University of the Health Sciences
Bethesda, Md.

1. Define multidrug-resistant (MDR) bacteria and its growing threat to healthcare.
2. Explain the mechanisms by which bacteria develop resistance to antibiotics.
3. Identify common MDR pathogens and associated healthcare-associated infections (HAIs).
4. Discuss the factors contributing to the emergence of MDR bacteria.
5. Describe strategies for preventing the spread of MDR bacteria in healthcare settings, including Infection Prevention and Control (IPC) and antibiotic/diagnostic stewardship efforts.
6. Evaluate how the Multidrug-Resistant Organism Repository and Surveillance Network’s (MRSN’s) analysis and tools can collaborate with local IPCs for MDR control.

Sabiha Khan, MD
Medical Officer
Office of Therapeutic Biologics and Biosimilars
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Silver Spring, Md.

Sarah Ikenberry, MA
Associate Director for Stakeholder Outreach and Education
Office of Therapeutic Biologic and Biosimilars
U.S. Food and Drug Administration
Silver Spring, Md.

1. Describe how biologics differ from small molecules (size, complexity, manufacturing) and explain why some biologics cannot be copied exactly.
2. Compare and contrast the development, statutory requirements, and approval process for new biologics and for biosimilars/interchangeables.
3. Explain the requirements for generics and biosimilars/interchangeables.
4. Identify resources available for health care providers to learn more about biosimilar and interchangeable products through the Purple Book Database of Licensed Biological Products and other FDA educational resources.

Steven Lin, MD
Clinical Professor
Chief, General Primary Care
Director, Stanford Healthcare AI Applied Research Team
Division of Primary Care and Population Health
Stanford University School of Medicine
Stanford, Calif.

1. Explain the basics of artificial intelligence (AI), machine learning, and generative AI.
2. Identify and describe ways AI is being used in primary care
3. Summarize key challenges in integrating AI into healthcare.
4. Discuss the ethical landscape of AI in clinical settings.
5. Develop a plan to integrate AI in clinical practice.

LaGuinn P. Sherlock, Au.D., CCC-A
Research Audiologist
Defense Centers for Public Health – Aberdeen 
Audiology and Speech Pathology Center
Walter Reed National Military Medical Center
Bethesda, Md.

Sarah Theodoroff, Ph.D., CCC-A
Interim Associate Director
VA National Center for Rehabilitative Auditory Research
Associate Professor, Department of Otolaryngology-
Head & Neck Surgery at Oregon Health & Science University
Portland, Ore.

1. Differentiate transient ear noise from tinnitus.
2. Identify the different types of tinnitus.
3. Describe the clinical pathway for urgent and nonurgent referrals.
4. List common co-occurring conditions.
5. Educate patients about tinnitus (i.e., what to say and not to say).

Eric Blackstone, Ph.D.
Bioethics Research Fellow
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Mass.

1. Summarize the current state of research regarding multi-cancer early detection (MCED) testing.
2. Identify current knowledge gaps and ethical issues raised.
3. Apply ethical principles to decisions about MCED testing.